A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

Jeffrey Melson Clarke,Gerard C. Blobe,John H. Strickler,Hope E. Uronis,S. Yousuf Zafar,Michael A. Morse,Evan Dropkin,Leigh Howard,Margot O'Neill,Christel Rushing,Donna Niedzwiecki,Hollie Watson,Emily Bolch,Christy Arrowood,Yingmiao Liu,Andrew B. Nixon,Herbert Hurwitz

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

2019

Jeffrey Melson Clarke
Gerard C. Blobe
John H. Strickler
Hope E. Uronis
S. Yousuf Zafar
Michael A. Morse
Evan Dropkin
Leigh Howard
Margot O'Neill
Christel Rushing
Donna Niedzwiecki
Hollie Watson
Emily Bolch
Christy Arrowood
Yingmiao Liu
Andrew B. Nixon
Herbert Hurwitz

Purpose This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal cancer.

Keywords:

Kinase
Refractory
Internal medicine
Maximum tolerated dose
Oncology
Colorectal cancer
Regorafenib
Tolerability
Activin receptor
Pharmacology
Medicine
Monoclonal antibody
Abdominal pain
Nausea
Adverse effect
Clinical trial
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations